← Back to Search

Virus Therapy

Calanolide A for HIV

Phase 1
Waitlist Available
Research Sponsored by Sarawak MediChem Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be at least 18 years old
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of calanolide A in HIV-infected adults who have not used anti-HIV drugs.

Who is the study for?
This trial is for HIV-infected adults over 18 who haven't used anti-HIV drugs before. Participants must have an HIV level of at least 5000 copies/ml and a CD4 count above 200 cells/mm3. They should agree to birth control use during the study and not have AIDS-related infections, certain cancers, severe fevers recently, or significant organ problems.Check my eligibility
What is being tested?
The trial tests the safety and effectiveness of calanolide A in patients with HIV who are new to treatment. It aims to determine if this drug can be a viable option for those who have never taken anti-HIV medications.See study design
What are the potential side effects?
Potential side effects of calanolide A may include reactions similar to other anti-HIV drugs such as nausea, headaches, fatigue, or allergic responses. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Sarawak MediChem PharmaceuticalsLead Sponsor
1 Previous Clinical Trials
32 Total Patients Enrolled

Media Library

(+)-Calanolide A (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT00005120 — Phase 1
Human Immunodeficiency Virus Infection Research Study Groups:
Human Immunodeficiency Virus Infection Clinical Trial 2023: (+)-Calanolide A Highlights & Side Effects. Trial Name: NCT00005120 — Phase 1
(+)-Calanolide A (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005120 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still capacity for additional participants in this research?

"The clinicaltrial.gov page reveals that this experiment, first published on April 1st 2000 and last modified June 23rd 2005, is no longer enrolling participants. However, there are presently 485 other trials in search of volunteers."

Answered by AI

Can I join this medical experiment as a participant?

"This clinical trial seeks 16 patients infected with HIV who are 18 years of age or older. The primary criterion for enrolment is meeting the minimum legal age requirement of 18."

Answered by AI

Has this treatment received authorization from the Food and Drug Administration?

"Due to the paucity of safety and efficacy data, this therapy receieved a score of 1 on our team's evaluation scale. This denotes that it is currently in Phase 1."

Answered by AI

Does this clinical trial restrict participants to those over 70 years of age?

"The precondition for eligibility to this medical trial necessitates that participants be between 18 and 65 years old. For individuals younger than 18, there are 108 clinical trials available; conversely, 353 clinical trials are catered towards senior citizens aged over 65."

Answered by AI

Are there multiple locales in the US running this experiment?

"Chicago Ctr for Clinical Research in Chicago, Illinois, Anderson Clinical Research in Pittsburgh, Pennsylvania, and Burnside Clinic in Columbia, South carolina are just some of the sites currently taking part. An additional 7 medical centres have also been enlisted to contribute participants."

Answered by AI
~1 spots leftby Mar 2025